

Participant identification number:

Local logo/letterhead

CONSENT FORM Impact of Semaglutide in Amyloid Positivity (ISAP) study										_	
											ease initial each oox if you agree
1	I confirm that I have read and understand the information sheet dated (version X.X) for the above study. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.									the	
2	I understand that my participation is voluntary and that I am free to withdraw at any point, without giving any reason, without my medical care or legal rights being affected.										
3	I understand that I will only be included in the study if I am found to be suitable during the screening assessments.								able		
4	I have been advised about the potential risks associated with taking part in this research and have taken these into consideration before consenting to participate.										
5	I have been advised as to what I need to do for this research (especially with regard to semaglutide intake) and I agree to follow the instructions given to me.										
6	I understand that relevant sections of my medical notes and data collected during the study may be looked at by members of the site study team, monitors and designated individuals from the University of Oxford, the funder (Novo Nordisk), regulatory authorities and the participating Universities/NHS Trust(s), where it is relevant to my taking part in this study. I give permission for these individuals to have access to my records.									eam, nder NHS	
7	I agree to my General Practitioner being informed of my participation in the study and of any abnormal results arising during the study that may be of clinical relevance. I agree to my GP providing researchers with health information relevant to my participation in the study in the event that I stop attending follow-up visits.										
8	are no at by a	t useful f doctor. I	or medic f a conce	al diag ern is ra	nosis, ar ised abo	or the stond that so ut a poss it is medi	ans ar ible ab	e not rou normality	tinely loc on my s	ked can,	

finding has clear implications for my current or future health.



## Local logo/letterhead

9		IHS								
	Imp as v safe with the des	nber, address) and parental College London to well as imaging. I underly identify me for the may personal information of the study troyed after analysing etronic patient record a	nple can orm for be							
10	I understand that the coded information collected about me will be used to support other research in the future, and may be transferred to, and stored at, a destination outside the UK and the European Economic Area for analysis. I understand this research may involve commercial organisations.									
11	I ag and	ded								
12	I agree to donate blood samples and consider these samples a gift to the University of Oxford and understand I will not gain any direct personal or									
40		ncial benefit from ther								
13	I understand and agree that my samples will be used in research aimed at understanding the genetic influences on disease and that the results of these investigations are unlikely to have any implications for me personally.									
14	I agree for my blood samples to be used in future research, here or abroad, which has ethics approval. I understand this research may involve commercial organisations.									
15	I agree to take part in the above study.									
Optional: I agree for my contact details to be kept in a secure databate purpose of contacting me about future ethically approved				cally approved studies. I	Yes					
			eeing to be contacted ther studies.	No						
Optional		•	an existing research eline ISAP assessme	Yes						
		referring researchers	No							
				N/A						
						-1				
Name of F	artic	<u> </u>	dd / mmm / yyyy Date	Signature						
			dd / mmm / yyyy							
Name of p	Signature									
When com	nplet	ed: 1 for participant (c	copy); 1 for researcher	site file (original)						

ISAP Informed Consent Form Impact of Semaglutide in Amyloid Positivity CI: Dr Ivan Koychev Version/Date: 5.0, 23 Aug 2023 IRAS Project number: 300550 REC Reference number: 22/WM/0013

Page 2 of 2